Clinical Trials

Amsterdam logistics center strengthens links in the clinical trial supply chain, streamlines hybrid and DCT conduct.

The improvement of blood analysis technology and the dawn of decentralized trials have prompted development of at-home sampling products that draw from a capillary.

Andrew W. Lo, PhD, a finance professor at the MIT Sloan School of Management and the director of the MIT Laboratory for Financial Engineering, discusses cultural differences between the scientific side of biopharma and the financial side.

Boehringer Ingelheim will assess how monitoring cough and crackles with the RESP Biosensor can be used to monitor the status of patients with this disease.

Rich Christie, MD, PhD, Chief Medical Officer at AiCure discusses the use of the company's technology in a clinical trial for PTSD.

Ongoing efforts for standardization key in making data usable and trustworthy.

The Digital Medicine Society (DiMe) CEO Jennifer Goldsack and Takeda’s Head of Digital Health Sciences, Data Sciences Institute Shoibal Datta describe the current landscape of digitized clinical trials and the decisions needed to fully utilize their potential.

What is next for DCTs after acceleration from COVID-19?

In this interview, Dr. David Lee Scher adds his perspective on how digital health is changing in both healthcare and clinical trial settings.

How DCTs can impact pharmaceutical companies exploring DTx combination products and standalone DTx studies.

Benefits of business 4.0 approach in EDC in med-dev studies.